Bioassay and NMR-HSQC-Guided Isolation and Identification of Phthalide Dimers with Anti-Inflammatory Activity from the Rhizomes of Angelica sinensis by Hongyan Wen (9226895)

“…Among them, compound <b>9</b> showed a remarkable inhibitory activity with IC₅₀ values of 425 nM and could significantly decrease IL-1β and IL-6 transcription levels. …”

<b>Tracking incidence classification changes across disturbances at Konza Prairie LTER</b> by Biana Qiu (22063271)

<b>The taste of rebirth: a dual exploration of Wuhuang pork Flavoromics and metabolomics</b> by Yiting Yang (19262941)

<b>IMPACT OF MULTIVITAMINS AND PROCESSED MEAT ON AGING: A MACHINE LEARNING APPROACH</b> by Mohcene M. (20142864)

<b>Supporting data for ''The pathogenicity and pathogenic mechanism of SARS-CoV-2 Omicron''</b> by Bingjie Hu (10835565)

“…Further mechanistic investigations reveal that the Omicron subvariant is ineffective in using TMPRSS2 compared with ancestral SARS-CoV-2 (HKU-001a) and previous variants, which may contribute to its decreased replication in Calu3 and Caco2 cells. In K18-hACE2 transgenic mice, the replication capacity of the Omicron subvariant is significantly attenuated in both the upper and lower respiratory tracts of virus-infected animals when compared to that of the ancestral strain and Delta (B.1.617.2) variant, correlating with substantially ameliorated lung pathology. …”

The effect of IFN-β and Vit D on the NF-κB and p-NF-κB protein. by Farzad Nasri (8941850)

“…IFN-β, Vit D, and the co-treatment all decrease p-NF-κB protein expression in comparison with the control, but it was only significant for the co-treatment group <b>(B)</b>. …”

Image 3_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.tiff by Qianyi Zhou (6196383)

“…Purpose<p>CD19 chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but cytokine release syndrome (CRS) remains a significant side effect.…”

Table 1_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.docx by Qianyi Zhou (6196383)

“…Purpose<p>CD19 chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but cytokine release syndrome (CRS) remains a significant side effect.…”

Image 2_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.tiff by Qianyi Zhou (6196383)

“…Purpose<p>CD19 chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but cytokine release syndrome (CRS) remains a significant side effect.…”

Table 2_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.doc by Qianyi Zhou (6196383)

“…Purpose<p>CD19 chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but cytokine release syndrome (CRS) remains a significant side effect.…”

Image 1_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.tiff by Qianyi Zhou (6196383)

“…Purpose<p>CD19 chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but cytokine release syndrome (CRS) remains a significant side effect.…”

Enrollment of patients in the study. by Bengt Wahlin (19959392)

“…</p><p>Results</p><p>After four weeks of treatment with HCQ, total cholesterol had decreased from 5.4 mmol/L to 5.1 mmol/L (p<0.001), low-density lipoproteins from 3,0 mmol/L to 2.7 mmol/L (p<0.001) and apolipoprotein B from 0.96 g/L to 0.90 g/L (p<0.01). …”

EU Data.csv<b>EU Data-1:</b> Age, sex, and medications used in patients with Parkinson’s disease.<b>EU Data-2:</b> Experimental parameters during off and on states of anti-Parkinso... by Eiichirou Urasaki (20502995)

Time series of validations on buses using <i>smart-cards</i> during the COVID-19 pandemic period in 2020. by Jorge L. B. Araújo (20324246)

Results of differential abundance assessment expressed as Log2 Fold Change (Log2FC) for comparison between different taxonomic groups after the intervention. by Adriana Bittencourt Campaner (21175462)

Fig 1 - by Taehyeong Kim (8991383)

<b>Species removal dampens the scale dependency of ecological determinism and stochasticity in coastal communities.</b> by Nelson Valdivia (600515)

<b>Circular RNA encoding relaxin-2 as a potential therapy for liver fibrosis</b> by jiewen zhong (21472721)

<b>Species richness, composition and dominance of core and climate relicts of African Miombo woodlands</b> by Justice Muvengwi (22631075)

 'Plan-B':  Impact of changes in the global funding landscape for Hepatitis B clinical and research programmes by marion delphin (13249479)

“…<p dir="ltr"><b>Introduction:</b> Major cuts have been made to the global funding landscape since the beginning of 2025, including pausing or cancellation of existing grants, and cuts to specific organisations providing health interventions including PEPFAR and USAID. …”